At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to...
Learn about the types of cancer immunotherapy including immune checkpoint inhibitors, ACT, therapeutic vaccines, and more.
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
At a recent AACR Special Conference, experts discussed emerging therapeutic options to overcome resistance to Bacillus Calmette-Guérin (BCG).
Researchers at the AACR Annual Meeting 2024 shared how AACR Project GENIE data is helping their studies.
A recap of the plenary sessions, cutting-edge science, clinical trials, and more covered by the AACR blog.
Researchers around the world are designing and implementing methods to increase access to cancer care in low-resource areas.
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
Dr. Alan D’Andrea spoke about a new grant looking for fresh perspectives in Fanconi anemia-related cancer research.
The closing plenary of the AACR Annual Meeting 2024 recapped basic science, prevention, clinical advances, and more.